Does Rallies show Form 4 insider transactions for AEON?

Yes. Rallies tracks AEON insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is AEON research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AEON. It does not provide personalized investment advice.

AEON (AEON Biopharma, Inc.) Stock Analysis - Insider Trades

AEON Biopharma, Inc. (AEON) is a publicly traded Healthcare sector company. As of May 21, 2026, AEON trades at $0.86 with a market cap of $22.49M and a P/E ratio of -0.22. AEON moved +0.91% today. Year to date, AEON is -23.64%; over the trailing twelve months it is +69.63%. Its 52-week range spans $0.38 to $115.57. Rallies surfaces AEON's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading AEON stock inside the company?

Recent AEON insider activity includes FISCHER JOST bought 60.00K, FISCHER JOST bought 60.00K, FISCHER JOST bought 50.00K, and Strathspey Crown Holdings Group, LLC sold 7.38M. Rallies tracks insider transaction dates, shares, prices, and estimated values.

AEON Key Metrics

Key financial metrics for AEON
Metric	Value
Price	$0.86
Market Cap	$22.49M
P/E Ratio	-0.22
EPS	$-3.95
Dividend Yield	0.00%
52-Week High	$115.57
52-Week Low	$0.38
Volume	553
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-39.22M
Gross Margin	0.00%

Recent AEON Insider Trades

FISCHER JOST bought 60.00K (~$29.25K) on May 21, 2025.
FISCHER JOST bought 60.00K (~$30.36K) on May 20, 2025.
FISCHER JOST bought 50.00K (~$24.94K) on May 19, 2025.
Strathspey Crown Holdings Group, LLC sold 7.38M (~$73.80M) on Aug 11, 2023.

Latest AEON News

AEON Biopharma Gains FDA Support and Slashes Debt Over 90% With $6M PIPE — May 14, 2026
AEON Biopharma Schedules June 17 Meeting, Cash Runway Into Q3 2026 — Apr 24, 2026
AEON Biopharma Gets NYSE Notice Over $55M Equity Deficit, Listing Plan Extended — Apr 3, 2026
AEON Raises $6M in PIPE, Cuts Debt 90% and Advances BOTOX® Biosimilar — Mar 30, 2026
AEON Biopharma Receives FDA Support for ABP-450 Analytical Strategy, Targets 2026 Milestone — Mar 25, 2026

AEON Analyst Consensus

AEON analyst coverage data. Average price target: $0.00.

Common questions about AEON

Who is trading AEON stock inside the company?: Recent AEON insider activity includes FISCHER JOST bought 60.00K, FISCHER JOST bought 60.00K, FISCHER JOST bought 50.00K, and Strathspey Crown Holdings Group, LLC sold 7.38M. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for AEON?: Yes. Rallies tracks AEON insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is AEON research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AEON. It does not provide personalized investment advice.